Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 1999

View Archived Issues

Sugen: Q4 and 1998 year-end highlights

Orion: 1998 year-end highlights

Aradigm: Q4 and 1998 year-end highlights

Techniclone to present clinical data on newly designated orphan drug at ASCO

Genelabs presents gene switch application

Merck Frosst presents clinical data on COX-2 inhibitor at Canadian meeting

Genzyme Molecular Oncology initiates clinical trials of combined-antigen melanoma vaccine

Zenapax shows positive results in GVHD trial

Enbrel advances to phase II/III trials for chronic heart failure; phase I results presented at ACC

New Drug Submission for Ditropan accepted for review in Canada

NeuroSearch's agreement with Pharmacia & Upjohn for NS-2710 ends; study results reported

Hyseq conducts preclinical testing on novel anticoagulant products

Anticancer glycosidase inhibitors related to swainsonine

Boehringer Ingelheim discloses novel series active against wild-type and mutant HIV-1 RT

Ziracin: lead compound from a new class of antibiotics in late-stage trials at Schering-Plough

Series from Lilly especially useful for hypercholesterolemia in postmenopausal women

Japanese pharmaceutical companies reveal collaborative research on MDR ligands

ICN launches Senetek's antiaging product

Yamanouchi describes novel anticoagulants

Plant-derived topoisomerase II inhibitors patented by Meiji Milk

Chiron's rFGF-2 featured at ACC meeting

Ultrasound imaging enhanced with AI-700 provides accurate assessment of CV disorders

Subanalyses of abciximab trial results presented at ACC meeting

Fragmin found to reduce heart attack and death at 45 days

ACC highlights: ASSENT 2 study supports improved efficacy of TNK-tPA over t-PA

FDA approves new therapy for type II diabetes

Novogen's phenolic hormone-derived anticancer drug shows potent activity against prostate cancer